Kythera Biopharmaceuticals Receives Notice of Allowance for Additional U.S. Patent on ATX-101 (Formulations of Deoxycholic Acid and Salts)
12/14/2011 8:32:35 AM
LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pharmaceutical formulation patent application that covers ATX-101, a first-in-class, injectable drug under clinical investigation for the reduction of submental (under the chin) fat. The patent to be issued from this allowed application, titled "Formulations of Deoxycholic Acid and Salts Thereof," carries a patent term to at least 2030. Similar applications have been filed with the European Patent Office (EPO) and the Patent Cooperation Treaty (PCT).